Orient Pharma Past Earnings Performance
Past criteria checks 3/6
Orient Pharma has been growing earnings at an average annual rate of 51.6%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 23.5% per year. Orient Pharma's return on equity is 6.7%, and it has net margins of 11.2%.
Key information
51.6%
Earnings growth rate
53.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 23.5% |
| Return on equity | 6.7% |
| Net Margin | 11.2% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Orient Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,066 | 119 | 357 | 84 |
| 31 Mar 24 | 978 | 71 | 351 | 92 |
| 31 Dec 23 | 890 | 22 | 344 | 100 |
| 30 Sep 23 | 767 | -13 | 278 | 107 |
| 30 Jun 23 | 644 | -48 | 212 | 115 |
| 31 Mar 23 | 578 | -38 | 140 | 122 |
| 31 Dec 22 | 512 | -29 | 68 | 129 |
| 30 Sep 22 | 544 | -25 | 62 | 146 |
| 30 Jun 22 | 576 | -21 | 56 | 163 |
| 31 Mar 22 | 520 | -62 | 56 | 191 |
| 31 Dec 21 | 463 | -103 | 56 | 220 |
| 30 Sep 21 | 451 | -170 | 57 | 242 |
| 30 Jun 21 | 427 | -173 | 57 | 242 |
| 31 Mar 21 | 419 | -172 | 58 | 213 |
| 31 Dec 20 | 412 | -171 | 58 | 184 |
| 30 Sep 20 | 412 | -162 | 60 | 155 |
| 30 Jun 20 | 388 | -177 | 61 | 142 |
| 31 Mar 20 | 371 | -189 | 63 | 148 |
| 31 Dec 19 | 354 | -201 | 65 | 154 |
| 30 Sep 19 | 302 | -168 | 69 | 157 |
| 30 Jun 19 | 285 | -176 | 72 | 165 |
| 31 Mar 19 | 277 | -168 | 71 | 176 |
| 31 Dec 18 | 270 | -160 | 69 | 186 |
| 30 Sep 18 | 254 | -185 | 66 | 196 |
| 30 Jun 18 | 238 | -210 | 64 | 207 |
| 31 Mar 18 | 233 | -237 | 61 | 210 |
| 31 Dec 17 | 229 | -265 | 59 | 214 |
| 30 Sep 17 | 248 | -236 | 59 | 208 |
| 30 Jun 17 | 261 | -214 | 61 | 203 |
| 31 Mar 17 | 268 | -207 | 62 | 197 |
| 31 Dec 16 | 274 | -199 | 64 | 192 |
| 30 Sep 16 | 229 | -223 | 54 | 195 |
| 30 Jun 16 | 200 | -233 | 49 | 193 |
| 31 Mar 16 | 177 | -235 | 47 | 187 |
| 31 Dec 15 | 153 | -237 | 45 | 182 |
| 30 Sep 15 | 191 | -203 | 46 | 168 |
| 30 Jun 15 | 217 | -178 | 43 | 158 |
| 31 Mar 15 | 225 | -161 | 41 | 156 |
| 31 Dec 14 | 232 | -145 | 39 | 155 |
| 30 Sep 14 | 208 | -158 | 41 | 155 |
| 30 Jun 14 | 184 | -170 | 44 | 156 |
| 31 Mar 14 | 182 | -173 | 47 | 152 |
| 31 Dec 13 | 180 | -176 | 50 | 148 |
Quality Earnings: 4166 has high quality earnings.
Growing Profit Margin: 4166 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4166 has become profitable over the past 5 years, growing earnings by 51.6% per year.
Accelerating Growth: 4166 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4166 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Return on Equity
High ROE: 4166's Return on Equity (6.7%) is considered low.